BioStock Investor Meeting: Interview with Elicera Therapeutics

Elicera Therapeutics, led by CEO Jamal El-Mosleh, is developing immuno-oncology drug candidates based primarily on oncolytic viruses and CAR T-cells. The product portfolio includes four drug candidates and the company has also developed the technology platform iTANK. BioStock interviewed El-Mosleh about Elicera’s work at the BioStock Investor Meeting in Stockholm.

See the full interview at biostock.se:

https://www.biostock.se/en/2022/09/biostock-investor-meeting-interview-with-elicera-therapeutics/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se